Companies › Sonnet BioTherapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SON-1010 Recombinant IL-12 fused to albumin-binding domain (FHAB) for albumin hitchhiking and tumor | IL12 | Phase 1 | Advanced Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05352750 | SON-1010 | Phase 1 | Advanced Solid Tumor | Oncology | Jun 2026 |
Strand Therapeutics Geneos Therapeutics Suzhou Abogen Biosciences Imunon VLP Therapeutics Kangabio AUSTRALIA enGene Inovio Pharmaceuticals Trogenix
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.